Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Civica Rx, a hospital group committed to manufacturing its own drugs, has picked the first drugs it will make and the contractor to make them.
Takeda says supplies of primary immune deficiency treatment Gammagard Liquid will remain spotty this year as it ramps up production at a new plant.
B. Braun Medical will invest $1 billion to build a new plant in Florida and expand two other facilities to help address U.S. IV fluid shortages.
The possible cross-contamination with peanut flour of Novartis' anemia drug Promacta occurred at a contract manufacturing site.
The FDA says Torrent finished product batches were out of spec 340 times in two years, but the company often approved them after retesting.
After manufacturing issues led ADMA Biologics to pull its primary immune deficiency disease drug Bivigam from the market, it's won a new FDA approval.
With an Ebola outbreak in Congo outrunning vaccination efforts, the WHO wants to use an experimental drug from Johnson & Johnson.
With FDA approval of Zolgensma expected soon, Novartis CEO Vasant Narasimhan is confident that the company's manufacturing network will meet demand.
Novartis may be struggling a bit in the U.S. with cancer drug launches, but it has a new market it can now explore: Saudi Arabia.
Merck & Co., which has been riding a wave of Gardasil sales, will invest $1 billion and add 100 jobs to expand production.
